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Abstract
Introduction: In pulmonary embolism (PE) without hemodynamic compromise, the prognostic value of right
ventricular (RV) dysfunction as measured by echocardiography, computed tomography (CT) or biological
(natriuretic peptides) markers has only been assessed in small studies.
Methods: Databases were searched using the combined medical subject headings for right ventricular dysfunction
or right ventricular dilatation with the exploded term acute pulmonary embolism. This retrieved 8
echocardiographic marker based studies (n = 1249), three CT marker based studies (n = 503) and 7 natriuretic
peptide based studies (n = 582). A meta-analysis of these data was performed with the primary endpoint of
mortality within three months after pulmonary embolism, and a secondary endpoint of overall mortality and
morbidity by pulmonary embolism.
Results: Patients with PE without hemodynamic compromise on admission and the presence of RV dysfunction
determined by echocardiography and biological markers were associated with increased short-term mortality (odds
ratio (OR) ECHO = 2.36; 95% confidence interval (CI): 1.3-43; OR BNP = 7.7; 95% CI: 2.9-20) while CT was not (ORCT =
1.54-95% CI: 0.7-3.4). However, corresponding pooled negative and positive likelihood ratios independent of death
rates were unsatisfactory for clinical usefulness in risk stratification.
Conclusions: The presence of echocardiographic RV dysfunction or elevated natriuretic peptides is associated with
short-term mortality in patients with pulmonary embolism without hemodynamic compromise. In contrast, the
prognostic value of RV dilation on CT has yet to be validated in this population. As indicated both by positive and
negative likelihood ratios the current prognostic value in clinical practice remains very limited.
Introduction
A pulmonary embolism (PE) is a common and serious
medical condition. The presence of shock or hemody-
namic instability, defined as a systolic blood pressure of
below 90 mm Hg or a drop of more than 40 mm Hg, is
a clinical marker of high-risk patients who may benefit
from early thrombolysis [1]. However, for those patients
who are assessed to be at low or intermediate clinical
risk but who are without hemodynamic compromise,
this risk benefit is less clear. To refine therapeutic stra-
tegies in this subgroup, a more precise risk stratification
is required with the hope that other patients who may
benefit from thrombolytic therapy can be identified.
It is recognized that elevation in markers of myocar-
dial ischemia and the presence of right ventricular dys-
function (RVD) have a negative prognostic impact, and
they may define this intermediate risk group. The patho-
physiology of RVD in a PE is thought to occur because
of a sharp increase in RV afterload from both mechani-
cal pulmonary arterial obstruction and serotonin-
mediated pulmonary vasoconstriction. The resulting
increases in wall stress and decreased oxygen supply
cause RV myocardial ischemia, which in turn reduces
left ventricular preload, cause of systemic hemodynamic
instability.
Serum levels of cardiac troponin are specific for myo-
cardial ischemia and infarction, and the prognostic
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meta-analysis [2]. The prognostic value of other biologi-
cal markers (for example, elevated natriuretic peptides),
echocardiography, or computed tomography (CT) has
been assessed only in small studies and recent meta-
analyses [3,4]. We conducted this meta-analysis to assess
the impact of echocardiographic, CT, and biological
markers of RVD in PE on all-cause mortality within
3 months in low- or intermediate-risk patients who had
no features of hemodynamic instability at presentation
as well as to determine their prognostic value in terms
of positive (PLR) and negative (NLR) likelihood ratios.
Materials and methods
Study objectives
The primary objective of this meta-analysis was to assess
the prognostic value of these three RVD markers to pre-
dict mortality within 3 months in patients with acute
PE. The secondary objective was to evaluate whether
these markers are associatedw i t hs h o r t - t e r mm o r t a l i t y
resulting from PE or with serious adverse events (SAEs)
in relation to RVD.
Study endpoints
The primary endpoint was all-cause mortality. Second-
ary endpoints include death resulting from PE and SAE.
Total death and death resulting from PE were adjudi-
cated by the authors of the individual studies. Death
resulting from PE was related to irreversible right heart
f a i l u r eo rr e c u r r e n te m b o l i s ma tu pt o9 0d a y s ’ follow-
up. SAEs were the composite of death and any of the
following adverse outcome events: shock, need for
thrombolysis, nonfatal PE recurrence, cardiopulmonary
resuscitation, mechanical ventilation, catecholamine
administration, and surgical embolectomy.
Search strategy
Database searches were performed in PubMed and the
Cochrane database by using the combined medical sub-
ject headings for ‘right ventricular dysfunction or right
ventricular dilatation’ with the exploded term ‘acute pul-
monary embolism’ and by scanning references in
retrieved articles and reviews. The retrieved studies were
examined to exclude duplicate or overlapping data.
Meeting abstracts were excluded because they could not
provide adequately detailed data and their results might
not be final.
Study eligibility
Studies were eligible only if they evaluated the role of
RVD on the primary endpoint and referred to subjects
with non-high-risk PE. High-risk PE was defined as
patients having shock or hypotension on hospital arrival.
Inclusion criteria were (a) use of echocardiography, CT,
or brain natriuretic peptide/pro-brain natriuretic peptide
(BNP/proBNP) biomarkers for detecting RVD in
patients with documented PE, (b) in consecutive
patients identified either prospectively or retrospectively,
(c) with a reported follow-up of at least 90 days, (d) for
the primary endpoint of death or SAEs (or both) in rela-
tion to RVD, and (e) and studies that permitted the cal-
culation of true positive (death with RVD), false positive
(survival with RVD), true negative (survival without
RVD), and false negative (death without RVD). Studies
were excluded if they were performed (a) to test the effi-
cacy or safety of thrombolysis or surgical embolectomy,
(b) in patients without a definite diagnosis of PE,
(c) with high-risk patients included, or (d) with fewer
than 20 patients.
Data extraction
The following information was extracted from each
study: first author, year of publication, and journal;
study population characteristics, including sample size;
number of patients with documented PE; gender; mean
age (and standard deviation); relative timing of RVD
assessment; definitions of RVD on echocardiography
and of RV dilatation on CT; technical characteristics of
the BNP test and threshold, including type and brand of
test used; and rate of short-term death or SAEs as pre-
viously defined according to RVD markers. Three inves-
tigators (GC, EC, and MaH) performed the data
extraction independently. Discrepancies were solved by
a consensus. The study was conducted in accordance
with the guidelines of the Meta-analysis of Observa-
tional Studies in Epidemiology (MOOSE) [5]. In this
meta-analysis, unlike in randomized controlled trials, no
generally accepted lists of appropriate quality criteria for
observational studies are available. Rather than produ-
c i n gas i m p l ea r b i t r a r yq u a l i t ys c o r e ,s p e c i f i cq u a l i t y
aspects such as the following were used to assess the
studies: control of confounding factors, minimization of
selection bias with a clear description of inclusion and
exclusion criteria, description of the baseline characteris-
tics of the cohort, completeness of the follow-up, clear
definition of study outcomes, relative timing of the RVD
marker assessment after patient admission, and whether
or not the investigator responsible for the RVD mea-
surements was unaware of the patients’ baseline charac-
teristics or clinical course. Disagreements were solved
by consensus.
Data synthesis and statistical analysis
Pooled estimates for sensitivity, specificity, PLRs and
NLRs, and odds ratio (OR) for the primary and second-
ary endpoints from individual studies were calculated by
using a random-effects model as point estimates with
95% confidence intervals (CIs). Although sensitivity and
Coutance et al. Critical Care 2011, 15:R103
http://ccforum.com/content/15/2/R103
Page 2 of 10specificity are well known as measures of diagnostic
accuracy, their results may be influenced by the preva-
lence of disease in tested subjects. The PLR (the ratio
between sensitivity and 1 - specificity) provides an esti-
mate of the probability of a positive test in a patient
with disease, and the NLR (the ratio between 1 - sensi-
tivity and specificity) gives an estimate of the probability
of a negative test among diseased subjects. Both likeli-
hood ratios are roughly independent from prevalence
rates, and there is consensus that a PLR of greater than
10 and an NLR of less than 0.1 provide reliable evidence
of satisfactory diagnostic performance. While likelihood
ratios are the recommended summary statistics for sys-
tematic reviews of diagnostic studies, predictive values
may also be of interest for clinicians, even if these values
vary widely in their dependence on disease prevalence.
Between-study statistical heterogeneity was assessed by
using the Cochran Q chi-square test and the I
2 test.
Separate analyses were performed on studies with the
different RVD markers. Publication bias was assessed
visually by examination of funnel plots. Statistical com-
putations were performed with SPSS 11.0 (SPSS Inc.,
C h i c a g o ,I L ,U S A ) ,M e t a - D i s c[ 6 ] ,a n dR e v i e wM a n a g e r
4.2, and significance testing was at the two-tailed 0.05
level.
Results
Description of studies
Searching performed until December 2009 allowed 15
studies to be included in this meta-analysis after the
study selection described in Figure 1. Among those stu-
dies, 3 presented both echocardiographic and BNP
results, leading to the analysis of 8 studies for echocar-
diographic markers of RVD (n = 1,249 patients) [7-14],
3f o rC Tm a r k e r s( n = 503) [15-17], and 7 assessing
natriuretic peptides (n = 582) [8,9,11,18-21]. The follow-
up period varied between the in-hospital period and
3 months. All but one study were performed in a single
center.
Right ventricular dysfunction as assessed by
echocardiography
The echocardiographic criteria for each study are shown
in Table 1, and all included a quantitative index of RV
dilatation. The delay between the diagnosis of PE and
performance of echocardiography varied between 1 and
48 hours. In these studies, the average mortality rate
was 5% (range 1% to 13.5%), and the unadjusted OR of
RVD in predicting death was 2.36 (95% CI 1.3 to 4.3),
with no significant statistical heterogeneity (Figure 2).
The pooled NLR of the RV dilation on echocardiogra-
phy to predict mortality was unsatisfactory (0.62, 95%
CI 0.41 to 0.92). The pooled sensitivity, specificity, nega-
tive (NPV) and positive (PPV) predictive values, and
NLRs and PLRs are summarized in Table 2 for both the
primary and secondary endpoints.
Right ventricular dysfunction as assessed by computed
tomography
RV dilatation criteria were the same in the three
included studies: right-to-left ventricular minor axis
dimension ratio of greater than 1, measured at the
widest points between the inner surface of the free wall
and the surface of the interventricular septum (Table 1).
All-cause mortality was not given in one study [15]. In
the two other studies, the average mortality rate was
7.3% (range 2.5% to 15%); however, RVD was not asso-
ciated with the death (Figure 2). The pooled sensitivity,
specificity, NPVs and PPVs, and NLRs and PLRs are
summarized in Table 2 for both the primary and sec-
ondary endpoints.
Right ventricular dysfunction as assessed by BNP/NT-
proBNP elevation
Of the seven included studies, only one used a prede-
fined cutoff value for N-terminal pro-brain natriuretic
peptide (NT-proBNP) [21]. Other studies used a cutoff
value derived from receiver operating characteristic
curve construction to determine the best threshold able
to predict complicated PE. Plasma concentrations of
NT-proBNP (enhanced chemiluminescence immunoas-
say; Roche, Basel, Switzerland [8,18,21]) and BNP (fluor-
escence immunoassay: Triage; Biosite Incorporated, San
Diego, CA, USA [9,11], and immunoradiometric assay:
Shionoria; Shionogi & Co., Ltd., Osaka, Japan [19,20])
were quantitatively assessed by using autoanalyzers. In
five studies [8,9,11,19,20], clinicians were blind to the
results of natriuretic peptides, and in the two remaining
studies [18,21], this information was not presented.
Overall, the average mortality rate was 8.1% (range 1.5%
to 15.7%), and the unadjusted OR of elevated natriuretic
peptides in predicting death was 7.7 (95% CI 2.9 to
20.2), with no significant statistical heterogeneity
between studies and between studies using BNP and
NT-proBNP (Figure 2). However, the NLR remains non-
optimal (0.26, 95% CI 0.1 to 0.6). The pooled sensitivity,
specificity, NPVs and PPVs, and NLRs and PLRs are
summarized in Table 2 for both the primary and sec-
ondary endpoints.
Discussion
This analysis indicates that RVD as assessed by echocar-
diography or elevated BNP/proBNP levels can help to
identify patients with PE without hemodynamic compro-
mise at increased risk of short-term death and adverse
outcomes. In contrast, CT markers, including RV dila-
t i o n ,w e r eu n a b l et oi d e n t i f yas i m i l a rr i s kg r o u p .H o w -
ever, given the limitations for each marker, their
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as detailed below.
Right ventricular dysfunction as assessed by
echocardiography
Although echocardiographic markers had an excellent
NPV and therefore should be able to predict a good
outcome efficiently (pooled NPV to predict overall mor-
tality: 98%, 95% CI 96% to 99%), this statistic is influ-
enced by the prevalence of death. As overall death rates
were low in this population of intermediate- and low-
risk patients (5%, range 1% to 13.5%), the NLR would be
a better assessment of its usefulness. The pooled NLR of
the RV dilation on echocardiography to predict mortal-
ity was unsatisfactory (0.62, 95% CI 0.41 to 0.92). Thus,
the prognostic value of the absence of RV dilation on
echocardiography remains uncertain. More importantly,
the definition of RVD differed greatly among the studies,
and patients with chronic obstructive pulmonary disease
were not excluded [10]. In addition, differentiation of
chronic and acute RV overload would be difficult using
standardized criteria (RV free wall thickness of greater
than 5 mm or tricuspid valve regurgitation jet velocity
of greater than 3.7 m/s or both). Other limitations
include publication bias, despite an exhaustive database
search, as demonstrated in the funnel plot: small nega-
tive or weakly positive studies are not published (data
not shown). Sensitivity analysis showed a significant loss
in predictive power of these markers after exclusion of
the small studies. However, the prognosis impact of
these markers remained statistically significant (data not
s h o w n ) .F i n a l l y ,w h e nc o mmon confounding factors
were controlled for by a multivariate analysis (performed
w i t ht h ed a t af r o mf i v es t u d i e s[8,10,12-14]), this effect
was apparent in only one study [12], thus diminishing
the importance of this marker further.
Right ventricular dysfunction as assessed by computed
tomography
Although CT scanning has a high availability and plays a
central role in the diagnosis of a PE, a role in determining
short-term prognosis is unclear. Detection of RV dilation
has been reported to be useful [22]. However, our analy-
sis demonstrated this to be of limited prognostic impor-
tance and is in agreement with the recent meta-analysis
by Sanchez and colleagues [4], who found no statistically
significant relation between RV dilatation on CT and
mortality among patients with non-high-risk PE.
In contrast to echocardiography, CT markers of RV
dilatation were homogeneous between studies. However,
Figure 1 Flow diagram for study selection. PE, pulmonary embolism; RVD, right ventricular dysfunction; SUDOC, Système Universitaire de
Documentation.
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Page 4 of 10Table 1 Characteristics of included studies
Author Study
design
Patients,
n
Delay Primary
outcome
SAE definition Follow-
up
Mortality,
%
RVD
definition
RVD,
%
HI, n Thrombolysis,
n (%)
Age,
years
Male,
%
CHF, % COPD,
%
TTE
Grifoni, et al.
[7]
Prosp 162
(209
a )
<1 hour Death Clinical worsening, death Hospital 4 1 in A1, A2,
B, G, H1
40 0
(47
excluded)
10
(5%)
65 ±
15
40 14 25
Kostrubiec,
et al. [8]
Prosp 98 <24 hours Death Death, vasopressor,
thrombolysis, CPR
40 days 13 A9 + C or
G+H 1
60 0 5
(5%)
63 ±
18
38 17 7
Pieralli, et al.
[9]
Prosp 61 <1 hour Death Death, PE recurrence, HI Hospital 6.5 1 in A1, A2,
B, C, G, H2
57 0 6
(10%)
75 ±
14
26 0 10
Jimenez, et
al. [10]
Prosp 214 <48 hours Death Not studied 30 days 3 1 in A1, A2,
C,F
40 0 NA NA 49 11.7 13
Logeart, et
al. [11]
Prosp 67 <19 hours Death Death, thrombolysis, HI Hospital 1.5 2 in A3, B, C,
D2, F
54 0 6
(9%)
64 60 0 NA
Zhu, et al.
[12]
Prosp 468
(520
a )
NA SAE Death, thrombolysis, CPR,
MV, embolectomy
14 days 1 2 in : A2 or
A6, C, D3, F
42 0
(52
excluded)
NA 57 ±
14
62 NA 8
Gallota, et
al. [13]
Prosp 90 <1 hour SAE Death, HI Hospital 13 1 in A5, B 72 0 NA 67 ±
18
28 44 11
Palmieri, et
al. [14]
Prosp 89 Admission SAE Death, HI Hospital 13.5 A4 + B + C 54 0 NA 63 ±
15
27 NA 10
Spiral CT
van der
Meer, et al.
[15]
Retro 120 NA Death
(PE)
Not studied 3
months
15 dRV/dLV >1 57.5 0 0 59 ±
18
46 NA NA
Moroni [16] Retro 226 NA Death Not studied 3
months
10.6 dRV/dLV >1 35 0 0 67 ±
17
50 14 6.5
Stein, et al.
[17]
Retro 157 NA Death Not studied 30 days 2.5 dRV/dLV >1 50 0 2
(1.3%)
56 ±
17
41 0 0
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NT-proBNP
Kostrubiec,
et al. [8]
Prosp 100 Admission Death Death, thrombolysis, CPR,
embolectomy, vasopressors
40 days 15 >600 pg/mL 39 0 5 62 ±
18
35 17 7
Pruszczyk,
et al. [18]
Prosp 70 Admission Death Death, thrombolysis, CPR,
embolectomy, vasopressors
Hospital 15.7 NA 83.5 0
(9
excluded)
86 3 ±
17
37 NA NA
Vuilleumier,
et al. [21]
Prosp 146 Admission Death - 3
months
3.4 300 pg/mL 60 0 0 NA 42 NA 5
BNP
Pieralli, et al.
[9]
Prosp 61 Admission
(<1 hour)
Death Death, HI, PE recurrence Hospital 6.5 >100 pg/mL 70 0 6 75 ±
14
26 Excluded 10
Logeart,
et al. [11]
Prosp 67 Admission Death Death, thrombolysis, CPR,
vasopressors
Hospital 1.5 >527 pg/mL 67 0 6 64 ±
16
60 Excluded NA
ten Wolde,
et al. [19]
Prosp 110 Admission Death Not studied 3
months
8.2 >21.7 pmol/
L
33 0 NA 58 ±
18
NA NA NA
Tulevski,
et al. [20]
Prosp 28 Admission
(<1 hour)
Death Not studied 90 days 7.1 >10 pmol/L 50 0 NA 53 ±
18
43 Excluded 0
aBefore exclusion of patients with high-risk pulmonary embolism (PE). Right ventricular dysfunction (RVD) definition: (A1) end diastolic right ventricular diameter (EDRVD) of greater than 30 mm; (A2) EDRVD/left
ventricular diameter (LVD) of greater than 1 in four-chamber view; (A3) EDRVD/LVD of greater than 0.7 in four-chamber view; (A4) EDRVD/LVD of greater than 0.9 in four-chamber view; (A5) EDRVD of greater than
15 mm/m
2 body surface area (BSA); (A6) EDRVD/LVD of greater than 0.6 in four-chamber view; (A7) EDRVD of greater than 4.5 cm in four-chamber view; (A8) right ventricular end diastolic area (RVEDA) greater than
left ventricular area (LVA) in four-chamber view; (A9) EDRVD/LVD of greater than 0.6 parasternal long axis; (B) paradoxal septal motion; (C) right ventricular free wall hypokinesia; (D1) tricuspid valve regurgitation (jet
velocity of greater than 2.5 m/s); (D2) tricuspid valve regurgitation (jet velocity of greater than 2.7 m/s); (D3) tricuspid valve regurgitation (jet velocity of greater than 2.8 m/s); (E) thrombi in right chambers; (F) loss of
inspiratory collapse of the inferior vena cava; (G) tricuspid valve pressure gradient (TVPG) of greater than 30 mm Hg; (H1) Doppler pulmonary acceleration time of less than 80 ms; (H2) Doppler pulmonary
acceleration time of less than 90 ms; (I) right pulmonary artery dilatation of greater than 12 mm/m
2 BSA. CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; CPR, cardiopulmonary resuscitation;
d, diameter; HI, hemodynamic instability; hospital, in-hospital follow-up; LV, left ventricle; MV, mechanical ventilation; NA, not applicable; prosp, prospective; retro, retrospective; RV, right ventricle; SAE, serious
adverse event; TTE, transthoracic echocardiography.
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0Figure 2 Odds ratio for death, based on the presence or absence of right ventricular dysfunction markers in acute pulmonary
embolism. BNP, brain natriuretic peptide; CI, confidence interval; CT, computed tomography; NT-proBNP, N-terminal pro-brain natriuretic
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four-chamber view with electrocardiogram gating are
more reliable than traditional measurements made on
the minor axis.
Our analysis had some limitations. For example, the
numbers of patients in this subgroup were small, the
majority of the studies were retrospective, and the clini-
cal presentation of patients included in studies is not
widely reported. Hence, any conclusions about the use-
fulness of this marker must be treated with some cau-
tion, and in the future, larger clinical studies and
standardized definitions of RV dilation will be required
in this patient subset.
Right ventricular dysfunction as assessed by BNP or
NT-proBNP elevation
The availability of biomarkers like BNP or proBNP
enables early identification of patients with RVD and
can contribute to risk stratification; this is potentially
important, especially when echocardiography assessment
is not available. We confirmed that BNP or proBNP
levels identified patients at higher risk of poor out-
comes, but because they had a low specificity and conse-
quently low PPV, their clinical use to identify those at
risk of mortality in this population may be limited.
Additionally, despite apparently superior diagnostic per-
formance, a direct comparison with echocardiographic
techniques for identifying those at risk of death may be
misleading as these biomarker-based studies appeared to
enroll populations of a higher average mortality in com-
parison with echocardiography (8.1%, range 1.5% to 15.7%
versus 5%, range 1% to 13.5%; P < 0.01). There was no evi-
dence of publication bias (funnel plot not shown). Multi-
variate analysis showed a stability of the prognosis value of
natriuretic peptides [18,19,21], with the exception of one
study [8].
Our analysis was limited by the small overall sample
size (n = 436), as demonstrated by the wide CI of the
calculated point estimates (Figure 2); as for echocar-
diography, despite an excellent NPV, the NLR remains
nonoptimal (0.26, 95% CI 0.1 to 0.6). Moreover, in
most of the studies, the cut points for BNP assays
were not predefined but were derived from receiver
operating characteristic curve construction to deter-
mine the best threshold able to predict a complicated
PE. Finally, BNP and NT-proBNP are nonspecific mar-
kers of wall ventricular stress and can be elevated in
clinical conditions other than PE, such as chronic
heart failure (CHF). The fact that only three of the
seven studies [9,11,20] excluded CHF patients could be
a potential source of bias as the majority of patients
with CHF have elevated BNP levels and are at higher
risk of mortality during PE in comparison with the
population without CHF.
Table 2 Pooled summary results of the prognostic value of right ventricular dysfunction markers
Number
of patients
Number
of studies
Odds ratio Sensitivity, % Specificity,
%
PLR NLR PPV, % NPV, %
TTE
Death all-
cause
1,249 8 2.36 (1.3-4.3) 74 (61-84) 54 (51-56) 1.4 (1.2-1.6) 0.62 (0.41-0.92) 7.6 (5.6-10) 97.6 (96-98.6)
TTE
PE-related
death
781 7 4.44 (1.75-11.3) 92 (78-98) 51 (48-55) 1.65 (1.4-2) 0.36 (0.2-0.8) 8.4 (6-11) 99 (98-100)
TTE
SAE
1,035 7 4.03 (2.76-5.9) 77 (71-83) 58 (54-61) 1.73 (1.5-1.9) 0.46 (0.3-0.6) 30 (26-34) 92 (89-94)
CT
Death all-
cause
383 2 1.54 (0.7-3.4) 46 (27-66) 59 (54-64) 1.3 (0.4-2) 0.8 (0.6-1.2) 8.3 (4.5-14) 93 (89-96)
CT
PE-related
death
277 2 2.17 (0.06-79) 87.5 (47-100) 48 (42-54) 1.2 (0.25-6) 0.51 (0.007-36) 5 (2-9) 99 (96-100)
CT
SAE
0 0- - -- ---
BNP-ProBNP
Death all-
cause
582 7 7.7 (2.9-20.2) 96 (86-100) 42 (38-46) 1.5 (1.2-1.9) 0.26 (0.1-0.6) 13 (10-17) 99 (97-100)
BNP-ProBNP
PE-related
death
436 6 6.4 (2-20) 97 (84-100) 42 (37-47) 1.5 (1.2-1.9) 0.3 (0.1-0.7) 12 (8-16) 97 (84-100)
BNP-ProBNP
SAE
228 3 15.6 (3-82) 100 (91-100) 36 (30-44) 1.5 (1.3-1.7) 0.01 (0.02-0.5) 26 (19-33) 100 (91-100)
Values are presented as numbers or as percentages (ranges). BNP-ProBNP, brain natriuretic peptide-N-terminal pro-brain natriuretic peptide; CT, computed
tomography; NLR, negative likelihood ratio; NPV, negative predictive value; PE, pulmonary embolism; PLR, positive likelihood ratio; PPV, positive predictive value;
SAE, serious adverse event; TTE, transthoracic echocardiography.
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The presence of echocardiographic RVD or elevated
natriuretic peptides is associated with short-term mor-
tality in patients with intermediate- and low-risk PE. In
contrast, the prognostic value of RV dilation on CT has
yet to be validated in this population. However, the clin-
ical utility of these markers is at risk of being overstated
given the number of limitations previously mentioned.
Based on the present analysis, the prognosis perfor-
mance of markers for RVD to predict death or adverse
outcomes is too low to be useful in routine practice for
patient management. Only large prospective studies will
be able to show whether the presence of such markers
or their combination, associated with markers of myo-
cardial ischemia, might justify initial aggressive treat-
ment in some subsets of patients.
Key messages
￿ Echocardiographic right ventricular (RV) dysfunc-
tion or elevated natriuretic peptides are associated
with short-term mortality in patients with pulmon-
ary embolism without hemodynamic compromise.
￿ The prognostic value of RV dilation on computed
tomography has yet to be validated in this
population.
￿ As indicated by both positive and negative likeli-
hood ratios, the current prognostic value of RV dys-
function markers remains very limited in clinical
practice.
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